Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Post Marketing Surveillance for General Drug Use to Assess the Safety and Efficacy Profile of ELONVA in Usual Practice

Trial Profile

Post Marketing Surveillance for General Drug Use to Assess the Safety and Efficacy Profile of ELONVA in Usual Practice

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Corifollitropin alfa (Primary)
  • Indications Infertility
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme; Organon

Most Recent Events

  • 31 Jan 2017 Status changed from active, no longer recruiting to completed.
  • 10 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jan 2017.
  • 12 Dec 2016 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top